U.S. Markets closed

Osiris Therapeutics price target raised to $14 from $11.50 at Piper Jaffray

Piper Jaffray increased its price target on Osiris after the company reported higher than expected biosurgery sales. The firm thinks that the company's Prochymal product, the first-ever approved stem cell therapy, could allow it to become profitable. It reiterates an Overweight rating on the stock.